「Inside CKD」多国微模拟模型揭示慢性肾脏病负担持续增加
Inside CKD项目采用微模拟模型,汇总31个国家和地区的已发表数据,评估慢性肾脏病(CKD)的临床与经济负担。结果显示,若维持当前低诊断率,至2027年CKD人群将增加5.8%,相关医疗费用增加9.3%;CKD筛查预计具成本效益并可适度延长预期寿命。
要点
- 若诊断率维持现状,2027年CKD人群将增5.8%、医疗费用增9.3%。
- CKD筛查预计具成本效益,并可适度延长预期寿命。
- 实施筛查与治疗策略对早期识别CKD、克服临床惰性至关重要。
核心结论
- 若当前低诊断率持续,CKD人群及相关医疗费用将持续增加。
- 实施筛查与治疗策略对早期识别和克服CKD管理临床惰性至关重要。
研究设计与样本
- Inside CKD项目采用微模拟模型预测CKD的临床与经济负担。
- 本研究评估了来自31个国家和地区的已发表Inside CKD数据。
主要发现
- 若维持当前低诊断率,至2027年CKD人群预计增加5.8%。
- 同期相关医疗费用预计增加9.3%。
- CKD筛查预计具成本效益,并可适度延长预期寿命。
临床怎么用
- 应实施CKD筛查策略以早期识别患者并改善管理。
- 需采取治疗策略以克服当前CKD诊断与管理的临床惰性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic kidney disease (CKD) affects approximately 1 in 10 people worldwide and is associated with increased morbidity and mortality, yet it remains underdiagnosed, undertreated, and underrecognized compared with other noncommunicable diseases. METHODS: The Inside CKD program uses a microsimulation model to project the clinical and economic burden of CKD. Here, we assessed published Inside CKD data, from 31 countries and regions, in the context of existing guidelines, recommendations, and other global initiatives. RESULTS: Our findings highlight that, if current low rates of diagnosis are maintained, the CKD population is projected to increase by 5.8%, with associated health care costs increasing by 9.3%, by 2027. Screening for CKD is also projected to be cost-effective and to modestly increase life expectancy. CONCLUSION: Implementing screening and treatment strategies will be crucial for the early identification of CKD and for overcoming the current clinical inertia around the diagnosis and management of CKD.
引用
- Wish J, Al-Ghamdi SM, Halimi JM, et al. "Inside CKD" Multinational-Microsimulation Modelling Insights Into the Increasing CKD Burden. Kidney Int Rep. 2025. PMID: 41141496. doi:10.1016/j.ekir.2025.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。